Four Moats. Compounding Daily.
The defensibility investors need to see at seed stage. Each moat is independently strong. Together, they create compounding barriers that widen over time.
0
Defensible Moats
0+
Years to Build
IP That Cannot Be Licensed
Korean Patent KR 10-1771125 covers the low-temperature cyclodextrin capture process that makes NanoActives possible. US patent pending for composition of matter. A competitor would need 3 to 5 years minimum to develop an alternative extraction method.
KR 10-1771125
Korean Patent Granted
0 to 5yr
Minimum to Replicate
20 Years of Process Parameters
Okchundang is a strategic equity investor, not a contract manufacturer. 3.1 million prescriptions fulfilled. 50K units/month capacity across 4 hGMP production lines with integrated QC/QA. This operational knowledge cannot be acquired through licensing.
0.0M+
Prescriptions
0K
Units/Month
0
hGMP Lines
0+
Years Experience
1,000+ Practitioners. 15 Years to Build.
Byung Kim built this network over 15 years through VUIM. These are not cold leads. They are 1,000+ alumni practitioners who trust the founders, understand TCM protocols, and serve high-intent patient populations. 20 owned clinic practitioners operate across Virginia, New Jersey, and Georgia. A competitor would need a decade or more to replicate this.
0+
VUIM Alumni
0
Owned Clinics
0yr
Network Built
Every Subscriber Widens the Gap
Every subscriber who pairs NanoActives with Pulse contributes to a proprietary dataset linking TCM interventions to biomarker outcomes. This data compounds over time. There is no shortcut.
~0K
Tongue Images
0K+
Pulse Records
Time to Replicate
Each moat is independently defensible. A competitor would need to overcome all four simultaneously.
| Moat | Status | Time to Replicate |
|---|---|---|
| Patent | Granted (Korea), Pending (US) | 3 to 5 years |
| Manufacturing | 3.1M+ prescriptions | 10+ years |
| Clinical Network | 1,000+ practitioners | Decade+ |
| Data Moat | Building with Pulse | Compounds over time |